About the Company
The Company is comprised of two business segments: OraSure, DNAG. The operations of CoreBiome, Diversigen and Novosanis are included in the DNAG segment. OraSure, located in Bethlehem, Pennsylvania, is a leader in the development, manufacture and distribution of point of care diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions. Its first-to-market, innovative products include rapid tests for the detection of antibodies to HIV and HCV on the OraQuick® platform, and oral fluid laboratory tests for detecting various drugs of abuse. OraSure's portfolio of products is sold globally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, research and academic institutions, distributors, government agencies, physicians' offices, commercial and industrial entities and consumers. OraSure's products enable healthcare providers to deliver critical information to patients, empowering them to make decisions to improve and protect their health. Given that OraSure's HIV and HCV products contain critical components.
DNAG, located in Ottawa, Canada, is the Company’s molecular collection segment which consists of the manufacture and sale of specimen collection kits that are used to collect, stabilize, transport and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome and animal genetics markets. CoreBiome and Diversigen provide microbiome laboratory testing and analytical services and Novosanis sells a device for the collection of first void urine samples in humans.
The Company is committed to conducting business in a lawful and ethical manner and is opposed to human trafficking and slavery. It is the Company's expectation that its suppliers will also conduct their business in such a manner and will comply fully with all laws and regulations, including those prohibiting slavery and human trafficking. The Company assesses its risk of human trafficking as low for the following reasons.